Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02970539
Recruitment Status : Recruiting
First Posted : November 22, 2016
Last Update Posted : June 17, 2019
Sponsor:
Information provided by (Responsible Party):
Athenex, Inc.

Brief Summary:
This is a nonrandomized, open-label, single group assignment, safety, tolerability and pharmacokinetic (PK) study to determine the MTD and optimal dosing regimen of Oraxol in combination with ramucirumab.

Condition or disease Intervention/treatment Phase
Gastric Cancer Esophageal Cancer Gastro-esophageal Cancer Drug: Oraxol Drug: Ramucirumab Phase 1

Detailed Description:
This is a sequential-group, dose escalation trial to determine the maximum tolerated dose of oral Oraxol in combination with intravenous ramucirumab. After a screening period of up to 28 days subjects will be enrolled into the treatment phase of the study. Each cycle of therapy will last 4 weeks. Subjects may continue in the study until they experience disease progression or unacceptable toxicity. Three to six subjects will be enrolled at each dose level. Once the tolerability of a dose level has been determined, an additional 3-6 subjects may be enrolled at a higher dose level, to determine the maximum tolerated dose. Safety will be monitored through recording of adverse events, serious adverse events, monitoring of laboratory tests including hematology, blood chemistry, urinalyses, physical examinations and electrocardiograms. Subjects will undergo radiographic assessments for tumor response at specified time points. Blood samples will also be obtained in the first cycle of therapy at multiple time points for determination of the amount of paclitaxel and metabolites and HM30181 in the circulation. After the treatment period, there will be a follow-up period during which the subject or family may be contacted every three months for follow-up.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b Study of Oraxol in Combination With Ramucirumab in Patients With Gastric, Gastro-esophageal, or Esophageal Cancers
Actual Study Start Date : December 8, 2016
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : December 31, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Ramucirumab

Arm Intervention/treatment
Experimental: Oraxol +Ramucirumab Drug: Oraxol
Oraxol (Paclitaxel and HM30181A) will be dosed orally. Paclitaxel will be supplied as capsules and HM30181A will be supplied as tablets.

Drug: Ramucirumab
Ramucirumab will be administered by iv infusion.




Primary Outcome Measures :
  1. Maximum tolerated dose (MTD) and dosing regimen of Oraxol as determined by dose limiting toxicity in patients with advanced stage gastric, gastro-esophageal, or esophageal cancers who are being treated with Oraxol in combination with ramucirumab [ Time Frame: One month ]
    The MTD will be the highest dose at which no more than 1 of 6 subjects experience a dose-limiting toxicity (DLT) during treatment and Oraxol pharmacokinetics (PK) are acceptable.


Secondary Outcome Measures :
  1. Safety assessments of adverse event (AE) and serious adverse event (SAE) information of Oraxol in combination with ramucirumab [ Time Frame: through study completion ]
    Safety assessments will consist of determining and recording all AEs (including for both increasing and decreasing severity) and SAEs

  2. Laboratory evaluation for hematology, blood chemistry and urine analysis [ Time Frame: through study completion ]
  3. Periodic measurement of vital signs [ Time Frame: From date of study start until the date of first documents progression or date of death from any cause, whichever came first, assessed up to 24 months ]
  4. The recommended Phase 2 dose of Oraxol in combination with ramucirumab [ Time Frame: One month ]
  5. The peak plasma concentration (Cmax) and Minimum plasma concentration (Cmin) [ Time Frame: Day 1 and 3: Predose, 8 timepoints up to 8 hours postdose; Day 2: Predose; Day 8 and 15: Predose, and between 1 and 3 hours postdose ]
  6. The amount of paclitaxel and HM30181A in blood stream by Area under the Concentration time curve (AUCt) and Area Under the Concentration of 0-8hours (AUC(0-8h)) [ Time Frame: Day 1 and 3: Predose, 8 timepoints up to 8 hours postdose; Day 2: Predose; Day 8 and 15: Predose, and between 1 and 3 hours postdose ]
  7. A biological half life or elimination half life (t 1/2) [ Time Frame: Day 1 and 3: Predose, 8 timepoints up to 8 hours postdose; Day 2: Predose; Day 8 and 15: Predose, and between 1 and 3 hours postdose ]
  8. The accumulation ratio (R) [ Time Frame: Day 1 and 3: Predose, 8 timepoints up to 8 hours postdose; Day 2: Predose; Day 8 and 15: Predose, and between 1 and 3 hours postdose ]
  9. The apparent volume of distribution of the drug in the body (Vd/F) [ Time Frame: Day 1 and 3: Predose, 8 timepoints up to 8 hours postdose; Day 2: Predose; Day 8 and 15: Predose, and between 1 and 3 hours postdose ]
  10. The apparent total clearance of drug from plasma (CL/F) [ Time Frame: Day 1 and 3: Predose, 8 timepoints up to 8 hours postdose; Day 2: Predose; Day 8 and 15: Predose, and between 1 and 3 hours postdose ]
  11. Response rate [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
  12. Progression-free survival [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months. ]
  13. Overall survival [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must meet all of the following criteria to be included in this study:

    1. Signed written informed consent 2. ≥18 years of age 3. Histologically or cytologically confirmed diagnosis of advanced stage gastric, gastro-esophageal (Part 1 or Part 2), or esophageal adenocarcinoma (Part 1 only) with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy 4. Have documented testing for HER2-neu overexpression, and for those with tumors overexpressing HER2-neu, have documented progression on Trastuzumab-containing therapy 5. Measurable disease on computed tomography (CT) scan of thorax, abdomen, and pelvis, per RECIST v1.1 criteria 6. Able to swallow oral medication as an intact dosage form 7. Adequate hematologic status as demonstrated by not requiring transfusion support or granulocyte-colony stimulating factor (G-CSF) to maintain:

    • ANC ≥1500 cells/mm3
    • Platelet count ≥100 x 109/L
    • Hemoglobin ≥10 g/dL; subjects with thalassemia having a hemoglobin <10 g/dL may be enrolled, per Investigator discretion 8. Adequate liver function as demonstrated by:
    • Total bilirubin of ≤1.5 mg/dL
    • Alanine aminotransferase (ALT) ≤3 x upper limit of normal (ULN) or ≤5 x ULN if liver metastasis is present
    • Alkaline phosphatase ≤3 x ULN or ≤5 x ULN if bone or liver metastasis is present
    • Gamma-glutamyl transferase (GGT) <10 x ULN 9. Adequate renal function as demonstrated by:
    • Serum creatinine ≤1.5 x ULN or creatinine clearance calculation ≥60 mL/min as calculated by the Cockcroft and Gault formula
    • Urinary protein ≤1+. If urinary protein is ≥2+, a 24-hour urine collection for protein must demonstrate <1000 mg of protein in 24 hours to allow participation in this protocol.

      10. Normal prothrombin time (PT) or international normalized ratio (INR) and normal activated partial thromboplastin time (aPTT) unless subject is on anticoagulation therapy 11. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 12. Life expectancy of at least 3 months 13. Women must be postmenopausal (>12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of study drug.

      14. Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of study drug.

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from this study:

  1. Unresolved toxicity from previous anticancer treatments, including investigational products (subjects must have recovered all unacceptable toxicity to ≤ Grade 1 Common Terminology Criteria for Adverse Events [CTCAE] toxicity). This does not extend to symptoms or findings that are attributable to the underlying disease.
  2. Received investigational products within 14 days or 5 half-lives of the first study dosing day, whichever is longer; subjects receiving biologic agents (eg, monoclonal antibodies) require a 30-day washout period.
  3. Are currently receiving other medications or radiation intended for the treatment of their malignancy
  4. Central nervous system metastases, including leptomeningeal involvement
  5. Women of childbearing potential who are pregnant or breastfeeding
  6. Currently taking a concomitant medication, other than a premedication, that is:

    • A strong P-glycoprotein (P-gp) inhibitor or inducer. Subjects who are taking such medications but who are otherwise eligible may be enrolled if they discontinue the medication ≥1 week before dosing
    • An oral medication with a narrow therapeutic index known to be a P-gp substrate within 24 hours prior to start of dosing in the study
    • Medications known to be strong inhibitors (gemfibrozil) or inducers (rifampin) of cytochrome P450 (CYP) 2C8 or medications known to be strong CYP3A4 inhibitors (eg, ketoconazole) or inducers (eg, rifampin or St. John's Wort). Subjects who are currently taking such medications but who are otherwise eligible may be enrolled if they discontinue the medication 1 week before dosing and remain off that medication during treatment with Oraxol.
  7. Use of warfarin. Participants receiving warfarin who are otherwise eligible and who may be appropriately managed with low molecular weight heparin, in the opinion of the Investigator, may be enrolled in the study provided they are switched to low molecular weight heparin at least 7 days prior to receiving study treatment.
  8. Require chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs), chronic antiplatelet therapy, dipyridamole, clopidogrel, or similar agents. Aspirin up to 325 mg per day is allowed.
  9. Unable to receive iv contrast for required CT scans
  10. Poorly-controlled hypertension (>160 mm Hg systolic or >100 mm Hg diastolic for >4 weeks) despite standard medical management. Subjects may be rescreened after adjustment of their antihypertensive medication.
  11. Serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to first dose of protocol therapy
  12. Prior history of GI perforation/fistula (within 6 months of first dose of protocol therapy) or risk factors for perforation
  13. Grade 3 or 4 GI bleeding within 3 months prior to first dose of protocol therapy
  14. Arterial thromboembolic event including, but not limited to, myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina within 6 months prior to first dose of protocol therapy
  15. Deep vein thrombosis (DVT) or pulmonary embolus or any other significant thromboembolic event during the 3 months prior to first dose of protocol therapy
  16. Child-Pugh Class B or C cirrhosis of the liver or cirrhosis (any degree) and a history of hepatic encephalopathy or a history of ascites resulting from cirrhosis requiring diuretics or paracentesis
  17. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, poorly controlled diabetes or diabetes with established vascular complications, chronic pulmonary disease requiring oxygen, known bleeding disorders, or any concomitant illness or social situation that would limit compliance with study requirements
  18. Medical condition that, in the opinion of the investigator, may interfere with oral drug absorption
  19. Major surgery within 28 days prior to first dose of protocol therapy, or minor surgery/subcutaneous venous access device placement within 7 days prior to the first dose of protocol therapy, or elective or major surgery planned to be performed during the course of the clinical trial
  20. History of hypersensitivity to paclitaxel, not attributed to a hypersensitivity type reaction to Cremophor®, or history of hypersensitivity type reaction to polysorbate 80 or other components of the formulation of Oraxol
  21. History of developing any condition during prior treatment with ramucirumab for which ramucirumab must be permanently discontinued according to the ramucirumab Investigator's Brochure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02970539


Contacts
Layout table for location contacts
Contact: E. Douglas Kramer, MD 908-272-0628 dkramer@kinexpharma.com
Contact: Ildiko Bezi 908-272-0628 ibezi@kinexpharma.com

Locations
Layout table for location information
United States, Texas
CTRC-UT Recruiting
San Antonio, Texas, United States, 78229
Contact: Lisa Creighton    210-450-1366      
Principal Investigator: Laura Tenner, MD         
Taiwan
China Medical University Hospital Recruiting
Taichung, Taiwan
Contact: Li-Yuan Bai, MD       lybai6@gmail.com   
Principal Investigator: Li-Yuan Bai, MD         
Tri-Service General Hospital Recruiting
Taipei, Taiwan, 11490
Contact: Ching-Liang Ho, MD         
Principal Investigator: Ching-Liang Ho, MD         
Taipei Veterans General Hospital Recruiting
Taipei, Taiwan
Contact: Yee Chao, MD. Phd       ychao@vghtpe.gov.tw   
Principal Investigator: Yee Chao, MD. Phd         
Lotung Poh-Ai Hospital Recruiting
Yilan, Taiwan, 26546
Contact: Hsien-Tang Yeh, MD         
Sponsors and Collaborators
Athenex, Inc.
Investigators
Layout table for investigator information
Study Director: E. Douglas Kramer, MD Kinex Pharmaceuticals Inc

Layout table for additonal information
Responsible Party: Athenex, Inc.
ClinicalTrials.gov Identifier: NCT02970539     History of Changes
Other Study ID Numbers: KX-ORAX-005
First Posted: November 22, 2016    Key Record Dates
Last Update Posted: June 17, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Esophageal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Head and Neck Neoplasms
Esophageal Diseases
Ramucirumab
Antineoplastic Agents